Download MendeleyDesign of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction.
Xu, S., Aguilar, A., Xu, T., Zheng, K., Huang, L., Stuckey, J., Chinnaswamy, K., Bernard, D., Fernandez-Salas, E., Liu, L., Wang, M., McEachern, D., Przybranowski, S., Foster, C., Wang, S.(2018) Angew Chem Int Ed Engl 57: 1601-1605
- PubMed: 29284071
- DOI: https://doi.org/10.1002/anie.201711828
- Primary Citation of Related Structures:
6B41 - PubMed Abstract:
The structure-based design of M-525 as the first-in-class, highly potent, irreversible small-molecule inhibitor of the menin-MLL interaction is presented. M-525 targets cellular menin protein at sub-nanomolar concentrations and achieves low nanomolar potencies in cell growth inhibition and in the suppression of MLL-regulated gene expression in MLL leukemia cells. M-525 demonstrates high cellular specificity over non-MLL leukemia cells and is more than 30 times more potent than its corresponding reversible inhibitors. Mass spectrometric analysis and co-crystal structure of M-525 in complex with menin firmly establish its mode of action. A single administration of M-525 effectively suppresses MLL-regulated gene expression in tumor tissue. An efficient procedure was developed to synthesize M-525. This study demonstrates that irreversible inhibition of menin may be a promising therapeutic strategy for MLL leukemia.
Organizational Affiliation:
Comprehensive Cancer and Departments of Internal Medicine, Pharmacology and Medicinal Chemistry, University of Michigan, 1600 Huron Parkway, Ann Arbor, MI, 48109, USA.
